Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...

Eli Lilly will invest $4.5 billion to construct the Lilly Medicine Foundry, a center aimed at finding better ways to make medicines. The investment seeks to build upon Lilly's success from ...

To learn more about how we handle and protect your data, visit our privacy center. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Daniel Ghinn explores the processes behind launching LillyPad, global pharmaceutical company Eli Lilly’s corporate blog, which has associated social media channels on YouTube, Facebook and Twitter.

Eli Lilly and Company (NYSE: LLY) today announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

Let's dig into Lilly's dividend history, and explore why I think a raise could come before year-end. On its corporate website, Eli Lilly's financial records date back to 1972. Back then ...

Last week, the Food and Drug Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name Mounjaro for diabetes and Zepbound for obesity. The move was a ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...

Insitro has teamed up with Eli Lilly to help power programs ... News of today's deals comes two months after Lilly opened a $700 million R&D center in the Boston Seaport intended to “push ...

The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now? Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.